Budesonide (targeted-release) · TARPEYO / Nefecon
Small molecule
Evidence outlook
Approved: IgA Nephropathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.
- Primary immunoglobulin A nephropathy (NEFECON, full approval of the sNDA)
- Kinpeygo is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
Nefigard NCT03643965 · Chronic Kidney Disease This randomized, quadruple-blind, placebo-controlled Phase 3 trial in 365 patients with biopsy-confirmed IgA nephropathy tested targeted-release budesonide against placebo, on top of standard blood-pressure-lowering therapy. Both co-primary endpoints were met: proteinuria (UPCR) fell significantly more on budesonide at 9 months, and kidney function (eGFR) declined significantly more slowly over 2 years, both with high statistical significance. Registry: NCT03643965 | 3 | Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline; Part B: Time-weighted Average of Estimated Glomerular Filtration Rate (eGFR) (Up to 2 years and 1 month) 2023-07-10 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1 (1)
What this study did
Competitive landscape
Other Glucocorticoid receptor drugs
albuterol / budesonide, Beclomethasone (QVAR), Betamethasone Dipropionate Emollient Spray, Budesonide (Entocort EC), budesonide (Ortikos) and 17 more. Compare all 23 Glucocorticoid receptor drugs
This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for IgA Nephropathy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Budesonide (targeted-Release) (TARPEYO / Nefecon): this drug | Approved | Small molecule | Glucocorticoid receptor | Reliable signal | No reviewed efficacy summary in this indication | |
| Albuterol / Budesonide (Airsupra) | Approved(overall) | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Atacicept | Approved | Protein / enzyme therapeutic | BLyS/APRIL (B-cell activating factor/a proliferation-inducing ligand) | Partial signal | Featured results are non-efficacy only in this race | |
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | Partial signal | NCT04573478: Primary (interim, first 270 patients): 24-hour UPCR change at week 36, atrasentan -38.1% vs placebo -3.1%; between-group difference -36.1 percentage points (95% CI -44.6 to -26.4), P<0.001 | |
| Beclomethasone (QVAR) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Betamethasone Dipropionate Emollient Spray (Sernivo) | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Budesonide (Entocort EC) | Approved(overall) | Small molecule | Glucocorticoid receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Budesonide (Ortikos) | ApprovedUS marketing discontinued (overall) | — | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Budesonide (Uceris Rectal Foam) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Budesonide MMX (Uceris) | Approved(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ciclesonide (Alvesco) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Dexamethasone | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Dexamethasone (Dextenza) | Approved(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Furoate (Arnuity Ellipta) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved(overall) | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Furoate / Vilanterol (Breo Ellipta) | Approved(overall) | Small molecule | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Propionate | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Propionate / Salmeterol (Advair HFA) | Approved(overall) | Combination | Glucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Halobetasol Propionate Foam (Lexette) | ApprovedUS marketing discontinued (overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Halobetasol Propionate Lotion (Bryhali) | Approved(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Hydrocortisone (Cortenema) | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Hydrocortisone Acetate (Cortifoam) | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Iptacopan (Fabhalta) | Approved | Small molecule | Complement Factor B | Partial signal | NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met. | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | Partial signal | NCT06291376: Primary 1, change in 24-hour UPCR at week 34 (prespecified interim analysis), ravulizumab vs placebo: the sponsor reports a statistically significant and clinically meaningful reduction, met; figures not yet published. Primary 2, change in eGFR at week 106: not yet reported; the trial is ongoing. | |
| Relacorilant (Lifyorli) | Approved(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Sparsentan (Filspari) | Approved | Small molecule | Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA) | Partial signal | Featured results are non-efficacy only in this race | |
| Lodotra (Rayos) | US approval withdrawn(overall) | — | Glucocorticoid receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Felzartamab | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| JADE101 | Phase 3 | Monoclonal antibody | APRIL (A Proliferation-Inducing Ligand, TNFSF13) | not yet graded | No reviewed efficacy summary in this indication | |
| Mezagitamab | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Povetacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Sefaxersen | Phase 3 | RNA / oligonucleotide | Complement factor B (CFB) | Partial signal | NCT05797610: Prespecified interim analysis: statistically significant reduction in proteinuria (24-hour UPCR) vs placebo at week 37 (2026-09-23). | |
| Telitacicept | Phase 3 | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| Zigakibart | Phase 3 | Monoclonal antibody | APRIL (A Proliferation-Inducing Ligand, TNFSF13) | not yet graded | No reviewed efficacy summary in this indication | |
| Dazucorilant | Phase 2(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ebribafusp Alfa | Phase 2 | Protein / enzyme therapeutic | C3d / Factor H | not yet graded | No reviewed efficacy summary in this indication | |
| Miricorilant | Phase 2(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| SCTC21C | Phase 1/2 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| ARO-CFB | Phase 1 | RNA / oligonucleotide | Complement factor B (CFB) mRNA | not yet graded | No reviewed efficacy summary in this indication | |
| Opemalirsen | Phase 1(overall) | RNA / oligonucleotide | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow TARPEYO / Nefecon (Budesonide (targeted-release)) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.